New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Tvardi Therapeutics, Inc.

TVRD

Healthcare Biotechnology

Tvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.

Revenue
+20.3%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

0.99 0.04 +4.21%

After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.

Market cap
$12.6M
P/E
n/m
Fwd P/E FY25e
n/m
Dividend yield
—
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.1×
Payout ratio
—

Tvardi Therapeutics, Inc. (TVRD) EV/Sales

Alert me on EV/Sales

As of Nov 20, 2026, Tvardi Therapeutics, Inc. (TVRD) trades at a EV/Sales of −1.3×. Over the past ten years it has ranged from −3.5× (February 2024) to 5,735× (March 2017); the current reading is higher than 7% of that period. That is below the Biotechnology industry median of 8.0× and below the Healthcare sector median of 3.1×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2024 6.4× —
FY2023 −2.9× —
FY2022 10.5× 215.08%
FY2021 3.3× (16.22%)
FY2020 4.0× (85.16%)
FY2019 26.9× 27.10%
FY2018 21.2× (93.14%)
FY2017 309× (87.18%)
FY2016 2,409× 2,873.16%
FY2015 81.0× —

Quarterly newest first

Period EV/Sales Change
Mar 2025 0.7× (89.83%)
Dec 2024 6.4× —
Sep 2024 −1.7× —
Jun 2024 −2.9× —
31 more quarters

Against its own ten years

Low −3.5× High 5,735×
Ten-year median 19.4×
Current reading's percentile 7

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on TVRD